During Monday’s Morning trade, Shares of Pandora Media Inc (NYSE:P), lost -0.67% to $13.35.
Mohr Davidow Ventures, one of Silicon Valley’s leading venture firms specializing in early-stage technology-based startups, recently declared that it will be hosting a private screening of CodeGirl, the latest documentary from Director Lesley Chilcott (executive producer of An Inconvenient Truth and Waiting for Superman). After the film — which follows ten teams of girls as they compete in Technovation, an entrepreneurship and coding competition — Katherine Barr, general partner at Mohr Davidow Ventures, will host a panel negotiation with some of Silicon Valley’s most accomplished women about how to close the gender gap that leaves women under-represented in the world of technology and science.
Although 74 percent of high school girls show an interest in science, technology, engineering or math, only 4 percent choose to major in these STEM subjects, and 50 percent of women in STEM careers leave the workforce. Computer programming, especially, is dominated by men, but the world’s first programmers were women. Even as late as the 1960s computer programming was considered a good career choice for young women1, but now women comprise just 18 percent of computer science undergraduate majors, down from 37 percent in 1985.
Barr, who appears in the movie, is passionate about eliminating this gender gap. “I give huge props to Tara Chklovski, Iridescent CEO, Technovation program founder, Anuranjita Tewary, and their team for growing the program to 5,000 participants worldwide this year,” says Barr. “I have been involved with Technovation as a judge for the past several years, and the documentary put into context what a big deal the Technovation Challenge is — it is having a global impact and changing girls’ lives by learning how to become technology entrepreneurs.”
Pandora Media, Inc. provides Internet radio services in the United States. The company allows listeners to create up to 100 personalized stations to access free music and comedy catalogs, in addition to offers Pandora One, a paid subscription service to listeners.
Shares of Potash Corporation of Saskatchewan (USA) (NYSE:POT), declined -0.05% to $20.33, during its current trading session.
Potash Corporation of Saskatchewan Inc., declared that its Board of Directors has declared a quarterly dividend of US $0.38 per share payable February 4, 2016 to shareholders of record January 14, 2016.
PotashCorp is the world’s largest crop nutrient company and plays an integral role in global food production. The company produces the three essential nutrients required to assist farmers grow healthier, more abundant crops. With global population rising and diets improving in developing countries, these nutrients offer a responsible and practical solution to meeting the long-term demand for food.
PotashCorp is the largest producer, by capacity, of potash and third largest producer of nitrogen and phosphate. While agriculture is its primary market, the company also produces products for animal nutrition and industrial uses. Common shares of Potash Corporation of Saskatchewan Inc. are listed on the Toronto Stock Exchange and the New York Stock Exchange.
Potash Corporation of Saskatchewan Inc., together with its auxiliaries, produces and sells fertilizers and related industrial and feed products worldwide. The company operates in three segments: Potash, Nitrogen, and Phosphate. It mines and produces potash, which is primarily used as fertilizer.
Finally, Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL), gained 1.76%, and is now trading at $4.63.
Anavex Life Sciences Corp., confirms the information in the November 9, 2015 press release announcing positive safety and cognitive efficacy data from the Phase 2a Alzheimer’s trial for ANAVEX 2-73.
Anavex confirms that there has been no change with regards to our science, data or the fundamentals of our Company. We remain dedicated to advancing ANAVEX 2-73 through the ongoing Phase 2a trial and to reporting new data to investors as it becomes available.
Anavex Life Sciences Corp., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer’s disease, central nervous system diseases, and pain and various cancers. Its lead drug candidates comprise ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), which is in a Phase IIa clinical trial for the treatment of Alzheimer’s disease.